Using the knowledge we gained in the pharmaceutical industry to create and offer the best CBD products.
It takes a best in class team to create best in class products.
Bringing over 80 years of pharmaceutical experience to the hemp industry.
Paul Johnson, Ph.D.
Co-Founder & Chief Scientific Officer
Dr. Johnson has over four decades of experience in the pharmaceutical industry. He is an expert in intranasal drug development and delivery systems, and authored or invented over 100 patents and scientific publications. Dr. Johnson has experience in drug delivery and development, molecular diagnostics, cell biology, molecular biology and biochemistry/biophysics. In addition, he has led research and development activities for FDA approved drugs including Betaseron, the first-ever FDA approved drug to treat multiple sclerosis. He received a B.S. in Molecular Biology from the State University of New York, a Ph.D. in Biochemistry from the Roswell Park Cancer Institute, and conducted his postdoctoral training in biophysics and biology under an American Cancer Society fellowship at the California Institute of Technology.
Dot Colagiovanni, Ph.D.
Vice President of Product Development
Dot has over two decades of pharmaceutical development experience with an emphasis on project management, pharmacology and toxicology. Prior to joining the company, Dr. Colagiovanni held scientific leadership roles with Nivalis Therapeutics and Replidyne. She also held research positions with OSI Pharma, Gilead Sciences and Amgen. Dr. Colagiovanni has a broad range of development experience, starting from early drug discovery and clinical trials through regulatory approval and commercial launch. She completed her Ph.D. at University of Colorado Health Sciences Center in Molecular Toxicology and a postdoctoral fellowship at Amgen Boulder.
Stephen Cape, Ph.D.
Director of Formulation Sciences
Dr. Cape has more than 15 years of experience developing formulations of pharmaceuticals, biologicals, and vaccines for alternative routes of delivery, including sublingual, nasal, transdermal, and inhalation. Prior to joining NFB, he held technical and project leadership roles at the University of Colorado and Aktiv-Dry LLC (Boulder, CO). Dr. Cape led the formulation and spray-drying process development of the first inhaled dry powder measles vaccine to successfully complete a Phase I clinical trial. He has a broad experience in early-stage basic R&D, formulation and process development, and technology transfer for GMP manufacturing.
Senior Analytical Chemist
Sue is a biotechnology professional with extensive experience in all stages of biopharmaceutical development from drug discovery to cGMP manufacturing. She has utilized numerous types of analytical instrumentation, from classical wet chemistry techniques for USP testing to HPLC, UPLC, and CE for protein characterization and impurity testing. She has held positions from Quality Control Chemist (Somatogen) working with recombinant hemoglobin to Associate Scientist (Amgen) where she helped bring Nplate (treatment for immune thrombocytopenia) from Phase 1 clinical trials to the commercial market.